Loading...
cholesterol homeostasis disruption→chemoresistance reversal→apoptosis
Statins disrupt cholesterol homeostasis critical for acute myeloid leukemia cell survival and chemoresistance, and early clinical studies suggest therapeutic potential as adjuncts to standard chemotherapy. Evidence includes case reports, early clinical trials, and in vitro/in vivo studies. This is an active repurposing area with promising but preliminary clinical evidence.
“Cholesterol homeostasis has been proposed as one mechanism contributing to chemoresistance in AML and hence, inclusion of statins in therapeutic regimens as part of clinical trials in AML has shown encouraging results.”
— Vesicular trafficking is a key determinant of the statin response in acute myeloid leukemia. (2021)DOI“Case reports and early clinical studies suggest a therapeutic potential for statins in acute myeloid leukemia (AML).”
— Antileukemic properties of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. (2013)DOI“e17018 Background: Recent studies have shown promising risk modifying effects of statin in various hematologic and solid tumors, such as its ability to induce apoptosis in acute myeloid leukemia cells in-vitro.”
— Survival outcome of veterans with myelodysplastic syndrome (MDS) treated with statins. (2012)DOI“We hypothesized that the use of statin improves response rate to tyrosine kinase inhibitor (TKI) therapy in patients with chronic myeloid leukemia (CML), thus increasing MR4.5 achievement and increasing the chance of being attempted TKI discontinuation.”
— The Use of Statin Enhances Chance of Achieving MR4.5 in Chronic Myeloid Leukemia Patients in Chronic Phase Following Imatinib Therapy (2014)DOI“Propensity Score Matching Analysis Demonstrates the Use of Statin Enhances Chance of Achieving MR4.5 in Chronic Myeloid Leukemia Patients in Chronic Phase Following Imatinib Therapy Regardless of Other Clinical Features Including Age of the Patients”
— Propensity Score Matching Analysis Demonstrates the Use of Statin Enhances Chance of Achieving MR4.5 in Chronic Myeloid Leukemia Patients in Chronic Phase Following Imatinib Therapy Regardless of Othe (2015)DOI“Statins Enhance the Molecular Response in Chronic Myeloid Leukemia when Combined with Tyrosine Kinase Inhibitors.”
— Statins Enhance the Molecular Response in Chronic Myeloid Leukemia when Combined with Tyrosine Kinase Inhibitors. (2021)DOI